Certa Therapeutics is proud to announce that our team members—Darren Kelly, Michelle Papdimitriou, and Simona Carbone—have published a thought-provoking article in the latest edition of Drug Discovery World. The article, titled “Is GPR68 a Potential Master Switch for Fibrotic and Inflammatory Diseases”, explores the pivotal role of GPR68 in driving inflammation and fibrosis across a range of diseases.
This publication comes at a significant time, with the article featured ahead of the JP Morgan Healthcare Conference, a key event in the biotech industry calendar.
In the article, the authors highlight Asengeprast, Certa Therapeutics’ first-in-class GPR68 proton-sensing antagonist, which has recently completed Phase IIa clinical trials for Systemic Sclerosis (SSc), also known as scleroderma. The data presented reinforces the potential of targeting GPR68 as a novel approach to addressing fibrotic and inflammatory diseases, areas of high unmet medical need.
The team are excited to see this important research gaining visibility within the biotech community. This publication underscores Certa’s commitment to advancing innovative treatments for patients with complex chronic diseases. Certa Therapeutics remains focused on leveraging its leading expertise in GPR68 antagonism to develop groundbreaking therapies for patients with debilitating fibrotic conditions.
Find the link to the winter 2024/2025 issue of DDW that features our article here.